Evaluation of emergency drug releases from the Centers for Disease Control and Prevention Quarantine Stations

Shahrokh Roohi, RN, MPH; Margaret Grinnell, BS; Michelle Sandoval, MPH; Nicole J. Cohen, MD; Kimberly Crocker, BSN, RN; Christopher Allen, RPh, MPH; Cindy Dougherty, PharmD, RPh; Julian Jolly, PharmD, RPh; Nicki Pesik, MD

doi:10.5055/jem.2015.0214

Authors

Shahrokh Roohi, RN, MPH
Margaret Grinnell, BS
Michelle Sandoval, MPH
Nicole J. Cohen, MD
Kimberly Crocker, BSN, RN
Christopher Allen, RPh, MPH
Cindy Dougherty, PharmD, RPh
Julian Jolly, PharmD, RPh
Nicki Pesik, MD

DOI:

https://doi.org/10.5055/jem.2015.0214

Keywords:

public health, botulism, diphtheria, malaria

Abstract

The Centers for Disease Control and Prevention (CDC) Quarantine Stations distribute select lifesaving drug products that are not commercially available or are in limited supply in the United States for emergency treatment of certain health conditions. Following a retrospective analysis of shipment records, the authors estimated an average of 6.66 hours saved per shipment when drug products were distributed from quarantine stations compared to a hypothetical centralized site from CDC headquarters in Atlanta, GA. This evaluation supports the continued use of a decentralized model which leverages CDC's regional presence and maximizes efficiency in the distribution of lifesaving drugs.

Author Biographies

Shahrokh Roohi, RN, MPH

Regional Officer in Charge, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Global Migration and Quarantine, Quarantine and Border Health Services Branch, Atlanta, Georgia.

Margaret Grinnell, BS

Public Health Associate, Centers for Disease Control and Prevention, Office for State, Tribal, Local and Territorial Support, Field Services Office, Atlanta, Georgia.

Michelle Sandoval, MPH

Quarantine Public Health Officer, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Global Migration and Quarantine, Quarantine and Border Health Services Branch, Atlanta, Georgia

Nicole J. Cohen, MD

Associate Chief of Science, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Global Migration and Quarantine, Quarantine and Border Health Services Branch, Atlanta, Georgia.

Kimberly Crocker, BSN, RN

Officer in Charge, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Global Migration and Quarantine, Quarantine and Border Health Services Branch, Atlanta, Georgia.

Christopher Allen, RPh, MPH

Senior Program Manager, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Scientific Resources, Drug Service, Atlanta, Georgia.

Cindy Dougherty, PharmD, RPh

Branch Chief, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Scientific Resources, Drug Service, Atlanta, Georgia.

Julian Jolly, PharmD, RPh

Senior Veterinary Pharmacist, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Scientific Resources, Drug Service, Atlanta, Georgia.

Nicki Pesik, MD

Branch Chief, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Global Migration and Quarantine, Quarantine and Border Health Services Branch, Atlanta, Georgia.

References

Offerman SR, Schaefer M, Thundiyil JG, et al.: Wound botulism in injection drug users: Time to antitoxin correlates with intensive care unit length of stay. West J Emerg Med. 2009; X(4): 251-256.

Centers for Disease Control and Prevention (US): Notice to readers: Availability of diphtheria antitoxin through an Investigational New Drug protocol. MMWR Morb Mortal Wkly Rep. 2004; 53(19): 413.

Centers for Disease Control and Prevention (US): Notice to readers: New medication for severe malaria available under an Investigational New Drug protocol. MMWR Morb Mortal Wkly Rep. 2007; 56(30): 769-770.

Food and Drug Administration (US): FDA approves first botulism antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes. 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345128.htm. Accessed February 4, 2015.

Centers for Disease Control and Prevention (US): Botulism from drinking prison-made illicit alcohol—Utah 2011. MMWR Morb Mortal Wkly Rep. 2012; 61(39): 782-784.